FN1 and breast cancer: We previously designed and developed an EDB-FN-targeted GBCA, ZD2-N3-Gd(HP-DO3A) (MT218), by conjugating the EDB-FN-specific peptide ZD2 to the clinical GBCA Gadoteridol 51, 52, and demonstrated its ability to facilitate efficient MRMI for risk-stratification of EDB-FN-rich prostate and breast cancers, even at doses as low as 20 μmol/kg (1/5th of the clinical dose), highlighting its translational applications and superior safety profile 51, 53.